MA43960A - Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 - Google Patents
Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1Info
- Publication number
- MA43960A MA43960A MA043960A MA43960A MA43960A MA 43960 A MA43960 A MA 43960A MA 043960 A MA043960 A MA 043960A MA 43960 A MA43960 A MA 43960A MA 43960 A MA43960 A MA 43960A
- Authority
- MA
- Morocco
- Prior art keywords
- hiv
- inhibitors
- compounds
- modified triterpenoids
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des composés ayant des propriétés thérapeutiques et bioactives, leurs compositions pharmaceutiques et leurs procédés d'utilisation. L'invention concerne, en particulier, des dérivés de l'acide bétulinique ayant une activité antivirale unique, qui sont utilisés comme inhibiteurs de maturation du vih, tels que représentés par des composés de formule i : ces composés s'avèrent utiles dans le traitement du vih et du sida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291298P | 2016-02-04 | 2016-02-04 | |
| PCT/IB2017/050568 WO2017134596A1 (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43960A true MA43960A (fr) | 2018-12-12 |
| MA43960B1 MA43960B1 (fr) | 2021-02-26 |
Family
ID=57995251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053358A MA53358A (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
| MA43960A MA43960B1 (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053358A MA53358A (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10421774B2 (fr) |
| EP (2) | EP3411381B1 (fr) |
| JP (1) | JP6735837B2 (fr) |
| KR (1) | KR102795662B1 (fr) |
| CN (1) | CN109153700B (fr) |
| AR (1) | AR107512A1 (fr) |
| AU (1) | AU2017215529B2 (fr) |
| BR (1) | BR112018015629B1 (fr) |
| CA (1) | CA3013417C (fr) |
| CL (1) | CL2018002084A1 (fr) |
| CO (1) | CO2018008157A2 (fr) |
| CR (1) | CR20180387A (fr) |
| CY (1) | CY1124353T1 (fr) |
| DK (1) | DK3411381T3 (fr) |
| DO (1) | DOP2018000174A (fr) |
| EA (1) | EA036211B1 (fr) |
| ES (2) | ES2862325T3 (fr) |
| HR (1) | HRP20210502T1 (fr) |
| HU (1) | HUE054337T2 (fr) |
| IL (1) | IL260741B (fr) |
| JO (1) | JOP20170029B1 (fr) |
| LT (1) | LT3411381T (fr) |
| MA (2) | MA53358A (fr) |
| MD (1) | MD3411381T2 (fr) |
| MX (1) | MX375118B (fr) |
| MY (1) | MY199668A (fr) |
| PE (1) | PE20181355A1 (fr) |
| PL (1) | PL3411381T3 (fr) |
| PT (1) | PT3411381T (fr) |
| RS (1) | RS61746B1 (fr) |
| RU (1) | RU2716502C2 (fr) |
| SG (1) | SG11201806388XA (fr) |
| SI (1) | SI3411381T1 (fr) |
| SM (1) | SMT202100210T1 (fr) |
| TW (1) | TWI719126B (fr) |
| UA (1) | UA123867C2 (fr) |
| UY (1) | UY37109A (fr) |
| WO (1) | WO2017134596A1 (fr) |
| ZA (1) | ZA201805044B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP3784349B1 (fr) | 2018-04-24 | 2023-12-27 | VIIV Healthcare UK (No.5) Limited | Composés ayant une activité inhibitrice de la maturation du vih |
| CN114786648A (zh) | 2019-12-09 | 2022-07-22 | Viiv保健公司 | 包含卡博特韦的药物组合物 |
| WO2024089216A1 (fr) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Nouveaux composés hétéroaryl-carboxamides contenant du soufre |
| WO2025037232A1 (fr) | 2023-08-11 | 2025-02-20 | ViiV Healthcare UK (No.4) Limited | Forme de sel de tosylate d'un inhibiteur de maturation pour le traitement du vih |
| WO2025068912A1 (fr) | 2023-09-27 | 2025-04-03 | ViiV Healthcare UK (No.3) Limited | Compositions pharmaceutiques |
| AU2023466962A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| GB0301227D0 (en) | 2003-01-20 | 2003-02-19 | Keen Group Ltd | Seating apparatus |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| AU2005224260A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| FR2956034B1 (fr) | 2010-02-09 | 2012-02-10 | Thales Sa | Dispositif d'entrainement pour des joueurs de rugby |
| ES2548905T3 (es) | 2010-06-04 | 2015-10-21 | Bristol-Myers Squibb Company | Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH |
| EP2576585B8 (fr) | 2010-06-04 | 2016-12-21 | VIIV Healthcare UK (No.5) Limited | Dérivés d'acide bétulinique modifiés en c-3, utilisés comme inhibiteurs de maturation du vih |
| DE102010017786A1 (de) | 2010-07-07 | 2012-01-12 | Continental Reifen Deutschland Gmbh | Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung |
| SI2670764T1 (sl) | 2011-01-31 | 2016-03-31 | Bristol-Myers Squibb Company | C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv |
| CA2826113C (fr) * | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | Triterpenoides modifies en c-17 et c-3 presentant une activite inhibitrice de la maturation du vih |
| AU2012352129B2 (en) * | 2011-12-14 | 2016-02-04 | Glaxosmithkline Llc | Propenoate derivatives of betulin |
| US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| WO2014100695A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US9378035B2 (en) | 2012-12-28 | 2016-06-28 | Commvault Systems, Inc. | Systems and methods for repurposing virtual machines |
| US20140221361A1 (en) * | 2013-02-06 | 2014-08-07 | Bristol-Myers Squibb Company | C-19 modified triterpenoids with hiv maturation inhibitory activity |
| CN105102468A (zh) * | 2013-02-25 | 2015-11-25 | 百时美施贵宝公司 | 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物 |
| CN104877015B (zh) * | 2014-02-28 | 2019-02-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种三萜-多肽缀合物、其药物组合物及用途 |
| PL3129392T3 (pl) | 2014-04-11 | 2021-04-06 | VIIV Healthcare UK(No.4) Limited | Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| HRP20220127T1 (hr) | 2016-02-04 | 2022-04-15 | Takeda Pharmaceutical Company Limited | Supstituirani spoj piperidina i njegova uporaba |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
-
2017
- 2017-02-01 AR ARP170100255A patent/AR107512A1/es active IP Right Grant
- 2017-02-02 TW TW106103410A patent/TWI719126B/zh active
- 2017-02-02 EA EA201891649A patent/EA036211B1/ru unknown
- 2017-02-02 MA MA053358A patent/MA53358A/fr unknown
- 2017-02-02 RU RU2018130181A patent/RU2716502C2/ru active
- 2017-02-02 EP EP17704093.8A patent/EP3411381B1/fr active Active
- 2017-02-02 MY MYPI2018702694A patent/MY199668A/en unknown
- 2017-02-02 PT PT177040938T patent/PT3411381T/pt unknown
- 2017-02-02 DK DK17704093.8T patent/DK3411381T3/da active
- 2017-02-02 UY UY0001037109A patent/UY37109A/es not_active Application Discontinuation
- 2017-02-02 MA MA43960A patent/MA43960B1/fr unknown
- 2017-02-02 HU HUE17704093A patent/HUE054337T2/hu unknown
- 2017-02-02 SG SG11201806388XA patent/SG11201806388XA/en unknown
- 2017-02-02 AU AU2017215529A patent/AU2017215529B2/en active Active
- 2017-02-02 WO PCT/IB2017/050568 patent/WO2017134596A1/fr not_active Ceased
- 2017-02-02 BR BR112018015629-9A patent/BR112018015629B1/pt active IP Right Grant
- 2017-02-02 MD MDE20181181T patent/MD3411381T2/ro unknown
- 2017-02-02 UA UAA201808249A patent/UA123867C2/uk unknown
- 2017-02-02 HR HRP20210502TT patent/HRP20210502T1/hr unknown
- 2017-02-02 ES ES17704093T patent/ES2862325T3/es active Active
- 2017-02-02 CR CR20180387A patent/CR20180387A/es unknown
- 2017-02-02 CA CA3013417A patent/CA3013417C/fr active Active
- 2017-02-02 LT LTEP17704093.8T patent/LT3411381T/lt unknown
- 2017-02-02 RS RS20210450A patent/RS61746B1/sr unknown
- 2017-02-02 MX MX2018009514A patent/MX375118B/es active IP Right Grant
- 2017-02-02 CN CN201780018790.8A patent/CN109153700B/zh active Active
- 2017-02-02 PE PE2018001378A patent/PE20181355A1/es unknown
- 2017-02-02 KR KR1020187025343A patent/KR102795662B1/ko active Active
- 2017-02-02 JO JOP/2017/0029A patent/JOP20170029B1/ar active
- 2017-02-02 SM SM20210210T patent/SMT202100210T1/it unknown
- 2017-02-02 ES ES21152161T patent/ES2957767T3/es active Active
- 2017-02-02 JP JP2018540806A patent/JP6735837B2/ja active Active
- 2017-02-02 PL PL17704093T patent/PL3411381T3/pl unknown
- 2017-02-02 EP EP21152161.2A patent/EP3831839B1/fr active Active
- 2017-02-02 SI SI201730647T patent/SI3411381T1/sl unknown
- 2017-02-02 US US16/071,925 patent/US10421774B2/en active Active
-
2018
- 2018-07-23 IL IL260741A patent/IL260741B/en active IP Right Grant
- 2018-07-26 ZA ZA2018/05044A patent/ZA201805044B/en unknown
- 2018-07-30 DO DO2018000174A patent/DOP2018000174A/es unknown
- 2018-07-31 CO CONC2018/0008157A patent/CO2018008157A2/es unknown
- 2018-08-02 CL CL2018002084A patent/CL2018002084A1/es unknown
-
2019
- 2019-08-07 US US16/534,208 patent/US11084845B2/en active Active
-
2021
- 2021-04-08 CY CY20211100303T patent/CY1124353T1/el unknown
- 2021-06-09 US US17/342,941 patent/US20210323997A1/en not_active Abandoned
-
2022
- 2022-12-16 US US18/083,037 patent/US20230295220A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43960B1 (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
| MA34909B1 (fr) | Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA39985B1 (fr) | 1h-pyrrolo [2,3-c]pyridine -7(6h)-ones et pyrazolo[3,4-c]pyridine-7(6h)-ones en tant qu'inhibiteurs de protéines bet | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| MA40886B1 (fr) | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA38483A1 (fr) | Inhibiteurs de l'ido | |
| WO2019035864A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA34170B1 (fr) | Inhibiteurs de transcriptase inverse non nucléosidiques | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA38182A1 (fr) | Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih) | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| MA39374A1 (fr) | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle | |
| MA41185B1 (fr) | Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc | |
| MA40149A1 (fr) | Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial | |
| MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA46563B1 (fr) | Compositions dispersibles | |
| MA42988B1 (fr) | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide | |
| MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta |